Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1083 combination influenza and COVID-19 vaccine in adults
NCT06864143Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Mar 2025
- Primary completion
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of mCOMBRIAX in influenza and coronavirus disease 2019 (COVID-19) (13 arms), sponsored by Moderna Inc. Primary endpoints: Geometric Mean Titer as Measured by Hemagglutination Inhibition Assay for Influenza at Day 29, Geometric Mean Concentration as Measured by Pseudovirus Neutralization Assay for SARS-CoV-2 at Day 29 and 3 more. Started Mar 2025; status: completed.
02
Drugs
mCOMBRIAX
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06864143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06864143.